Compare Eli Lilly And Co (LLY) vs Microsoft (MSFT) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Microsoft (MSFT) trades at $393.82, down 1.82% over the past day, with a bullish technical signal from moving averages and support near $390. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $4.27 exceeding the $4.06 estimate. Revenue growth remains robust, reaching $281.72 billion in 2025, and analyst sentiment is overwhelmingly positive with an 80.49% buy rating.

The outlook for MSFT is favorable, driven by AI leadership, cloud momentum, and consistent profitability, though risks include elevated capital expenditure concerns and competitive pressures. The consensus price target of $546.70 implies significant upside, supported by solid cash flow generation and a strong balance sheet.